Compare · BDX vs PRCT
BDX vs PRCT
Side-by-side comparison of Becton Dickinson and Company (BDX) and PROCEPT BioRobotics Corporation (PRCT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and PRCT operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $51.69B, about 41.8x PRCT ($1.24B).
- PRCT has been more active in the news (11 items in the past 4 weeks vs 10 for BDX).
- Both have 25 recent analyst ratings on file.
- Company
- Becton Dickinson and Company
- PROCEPT BioRobotics Corporation
- Price
- $189.79-0.43%
- $21.61+1.79%
- Market cap
- $51.69B
- $1.24B
- 1M return
- +19.45%
- -
- 1Y return
- -2.22%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 10
- 11
- Recent ratings
- 25
- 25
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
Latest BDX
- EVP, Chief Revenue Officer Feld Michael covered exercise/tax liability with 1,049 shares, decreasing direct ownership by 5% to 19,885 units (SEC Form 4) (for withholding tax)
- BD Appoints Gary Sorsher as Chief Quality Officer; Jeff Silvestri to Retire
- Chairman, CEO and President Polen Thomas E Jr exercised 43,278 shares at a strike of $167.25, returned $7,238,310 worth of shares to the company (39,126 units at $185.00) and sold $768,120 worth of shares (4,152 units at $185.00) as part of a pre-agreed trading plan (SEC Form 4)
- EVP and President, EMEA Goette Roland sold $440,888 worth of shares (2,438 units at $180.84), decreasing direct ownership by 14% to 14,856 units (SEC Form 4)
- BD Accelerates Advanced Tissue Regeneration Strategy with Landmark PREVENT Trial
- SEC Form 4 filed by Director Huffines Robert Luther
- SEC Form 4 filed by Director Byington Carrie L
- SEC Form 10-Q filed by Becton Dickinson and Company
- Becton Dickinson and Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- BD Reports Third Quarter Fiscal 2026 Financial Results
Latest PRCT
- PROCEPT BioRobotics® to Attend the Baird 2026 Global Healthcare Conference on September 15, 2026
- EVP, Chief Technology Officer Templin Barry L was granted 26,246 shares, increasing direct ownership by 38% to 95,199 units (SEC Form 4)
- EVP, CLO, CORP. SEC. Nouri Alaleh was granted 22,965 shares, increasing direct ownership by 22% to 128,034 units (SEC Form 4)
- EVP, CFO Waters Kevin was granted 29,527 shares, increasing direct ownership by 20% to 180,728 units (SEC Form 4)
- Chief Strat/Marketing Officer Sharma Pooja was granted 23,622 shares, increasing direct ownership by 27% to 111,181 units (SEC Form 4)
- President, CEO Wood Larry L bought $498,315 worth of shares (23,900 units at $20.85) (SEC Form 4)
- SEC Form 10-Q filed by PROCEPT BioRobotics Corporation
- PROCEPT BioRobotics downgraded by William Blair
- PROCEPT BioRobotics downgraded by Wells Fargo with a new price target
- PROCEPT BioRobotics Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits